Navigation Links
Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications

ANN ARBOR, Mich., May 16, 2012 /PRNewswire/ -- Rubicon Genomics, Inc., a leader in the development and commercialization of sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for research and clinical testing, today announced the launch of the first product in its innovative ThruPLEX™ family of sample preparation kits designed and optimized for next generation sequencing (NGS).  ThruPLEX-FD kits leverage Rubicon's patented DNA repair and ligation methods to deliver significantly faster and more sensitive sequencing of plasma, formalin-fixed, ChIP and other fragmented DNA with substantially increased throughput.  ThruPLEX kits are also applicable to sample preparation for PCR and microarray testing.

"The accelerated adoption of NGS technology has created a demand for faster and more sensitive sample preparation," noted James Koziarz, CEO of Rubicon.  "Breaking with the traditional multi-step process requiring intermediate transfers and purifications, ThruPLEX uses more efficient enzymology to repair, ligate and amplify the DNA molecules in a single tube.  Our patented three-step process enables high quality sequencing of clinical samples that were previously too small or degraded to be tested."

Henry Long, Ph.D., Associate Director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute, commented, "Our experience with the ThruPLEX-FD library prep has been extremely positive.  Both at Rubicon and in our hands it has proven able to generate high quality, diverse libraries from 10-times less input than other kits we have used.  For us this technology truly enables the study of samples that simply weren't possible before adopting it."

ThruPLEX-FD is a streamlined one-tube, three-step process without intermediate purifications, transfers, columns or gels.  The reduced steps and material transfers decrease the likelihood of experimental variability, bias and contamination.  DNA is sequencing-ready in two hours with as little as 15 minutes of hands-on time.  A technician can prepare 192 ThruPLEX samples a day—a 15-fold increase in productivity compared to current methods.  ThruPLEX-FD is designed and validated for use with samples as small as 50 picograms of human DNA and can be used in plasma, FFPE, cDNA, ChIP and population studies.  ThruPLEX-FD is currently available as 48-reaction, 12-index kits for sequencing on Illumina® HiSeq®, MiSeq® and Genome Analyzer instruments.  ThruPLEX-FD kits are also being developed for additional formats and platforms.

Mr. Koziarz continued, "ThruPLEX-FD highlights the power of this new technology, producing accurate and reproducible results from very small amounts of fragmented DNA.  We believe our ThruPLEX products will facilitate wider use of NGS and look forward to releasing additional ThruPLEX products later this year."

For more information about ThruPLEX-FD, visit

Separately, Rubicon announced that Kenneth Solomon has joined the company as Director, Sales and Marketing.  Mr. Solomon has extensive experience in marketing, sales and sales management for technologically advanced biomedical products, holding positions of increasing responsibility at Centocor Ortho Biotech, Pharmacia/Searle, Biomet, Boehringer Mannheim and others.

Mr. Koziarz commented, "Ken is a seasoned sales professional who brings us a track record of success in building market and product awareness for innovative biomedical products in both large and start-up companies.  He has managed sales organizations addressing a variety of biomedical customers, including academic and research centers.  As we further expand our product line of advanced pre-analytical amplification technologies, Ken will be instrumental in establishing Rubicon as a premier company in this rapidly growing sector."

About Rubicon GenomicsRubicon Genomics, Inc. is a leader in the development and commercialization of sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for research and clinical testing.  The company's core competency is the creation of more efficient molecular biology tools for genetic, epigenetic and expression analysis of difficult clinical samples to facilitate gene-based research, drug development, diagnostics and forensics.  Privately held Rubicon is located in Ann Arbor, Michigan.  For more information, visit Genomics

MediaJames Koziarz 

Barbara Lindheim Chief Executive Officer 

BLL Partners, LLC 

(212) 584-2276


SOURCE Rubicon Genomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use
2. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
3. Empire Genomics Chooses Funakoshi as Japan Distributor
4. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
5. Everist Genomics Develops Worlds First Comprehensive Companion Diagnostics and Prognostics Portfolio for Early Diagnosis and Improved Treatment of Colorectal Cancer
6. Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
7. Synthetic Genomics, Inc. and Integrated DNA Technologies, Inc. Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology
8. Smartphone Technology Meets Personalized Medicine in Everist Genomics CardioDefender Diagnostic System
9. AccuGenomics to Attend OneMedForum with Standardized Gene Expression Tests for Leukemia and Lung Cancer
10. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
11. Everist Genomics to Launch CardioDefender: Worlds Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians
Post Your Comments:
(Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):